Table 2.
Effects of sanglifehrins and CsA on replicons Huh 5-2 and Huh 9-13 (1b)
| Cyclophilin inhibitor | Huh 5-2 |
Wild-type Huh 9-13 |
CsAres Huh 9-13 |
||||||
|---|---|---|---|---|---|---|---|---|---|
| EC50a (nM) | CC50b (μM) | SIc | EC50 (nM) | CC50 (μM) | SI | EC50 (nM) | CC50 (μM) | Wt/res ratiod | |
| SfA | 320 | 9.1 | 29 | 619 | 7.3 | 12 | 308 | 6.8 | 0.5 |
| SfB | 71 | 4.6 | 64 | 164 | 4.2 | 26 | 51 | 6.7 | 0.3 |
| SfC | 1,600 | >100 | >62 | 1,100 | 40 | 38 | 1,300 | >20 | 1.3 |
| SfD | 262 | 3.8 | 14 | 1,000 | 332 | 30 | 871 | 3.3 | 0.9 |
| CsA | 306 | 4.4 | 14 | 415 | 8.8 | 21 | 3,880 | 7.9 | 9.3 |
a
EC50 is the concentration of compound required to reduce the replicon content by 50% as measured by either the luciferase (Huh 5-2) or the RT-qPCR assay (Huh 9-13).
b
CC50 is the concentration of compound required to inhibit the exponential proliferation of the cells by 50% as determined by the MTS assay.
c
In vitro selectivity index (SI) = CC50/EC50.
d
Wt, wild type; res, resistant replicon.